Silteplase
Alternative Names: Plasminer; Sinteplase; TD 2061Latest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation
- Developer Daiichi Pharmaceutical; Toyobo
- Class Plasminogen activator enzymes; Thrombolytics
- Mechanism of Action Plasminogen activator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Market Withdrawal Myocardial infarction
Most Recent Events
- 08 Jan 1997 Withdrawn for Myocardial infarction in Japan (Injection)